What Medical Excellence Capital does

Medical Excellence Capital (MEC) is an early-stage life sciences venture capital firm founded in 2020 by John Prufeta and headquartered in New York. The firm manages a $145 million debut fund raised in August 2022 and deploys capital into company creation, seed, Series A, and Series B opportunities spanning gene therapy, cell therapy, synthetic biology, regenerative medicine, and AI/ML-enabled drug discovery. MEC's core proposition is its proprietary national medical network of 1,100+ physician-scientists across 30+ academic medical centers and 130+ Expert Council members, accessed through its alignment with Medical Excellence Group (MedEx); deal flow is further amplified by 300+ family office relationships that simultaneously serve as limited partner pipeline.

The firm is purpose-built around five Managing Partners: John Prufeta (CEO, also founder of MedEx), Eric Heil (co-founder of Upward Health and RightCare Solutions, board chair of ProJenX), Brian Halak (formerly Partner at Domain Associates since 2006, co-founder of Nobias Therapeutics and WindMIL Therapeutics), Kim Kamdar (founding CEO of Aspen Neuroscience, chair of Truvian), and Joni Mancini (oversight of fund financial operations, formerly CFO at Artemis Wealth Advisors). Scientific capacity is being extended by MD and PhD research staff (Max Colbert, Victoria Lewis, Tess Marvin) and legal/operations support. The active portfolio of 17+ companies includes Aspen Neuroscience, Avilar Therapeutics, ClicBio, GC Therapeutics, Immunitas Therapeutics, Ladder Bio, Nobias Therapeutics, Pleno, ProJenX, SonoThera, Trotana Therapeutics, Truvian, and TwoStep Therapeutics.

MEC operates a two-pronged economic model: standard venture fund management fees on committed capital (approximately 2% on the $145M fund) plus carried interest on exits above the hurdle rate, with revenue realization dependent on successful IPO or M&A outcomes of portfolio companies. Differentiating the firm from other early-stage life sciences investors is the parallel MERIT (Medical Excellence Research Innovation Trust) philanthropic platform housed under the Medical Excellence Foundation 501(c)(3), which issues non-dilutive grants to bridge the translational 'valley of death' and feeds de-risked science into MEC's venture pipeline. The firm has begun cross-border activity through a May 2026 MoU between affiliated Medical Excellence Japan and India's Yamuna Expressway Industrial Development Authority for a 350-acre Medical Device Park in Noida.

Name

Medical Excellence Capital

Legal name

Medical Excellence Capital, LLC

Website

https://medexcelcap.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Medical Excellence Capital is an early-stage life sciences venture fund managing a $145 million debut fund. The firm invests in seed through Series B rounds across gene therapy, cell therapy, AI/ML drug discovery, and regenerative medicine, sourcing proprietary deal flow through a 1,100+ physician-scientist network spanning 30+ academic medical centers.

Ownership category

akta.pro rank

Product category

Venture Capital - Life Sciences

NAICS

Miscellaneous Financial Investment Activities (523999), Portfolio Management and Investment Advice (523940), Open-End Investment Funds (525910)

akta.pro primary industry

Corporate Venture Capital (CVC) (FSANAAAF)

Keywords

• Early-stage venture capital
• Life sciences investing
• Precision health funding
• Biotech seed funding
• Company creation ventures

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Fund Management & Carried Interest: MEC generates returns through management fees on committed capital and carried interest (typically 20%) on fund returns above the hurdle rate. Revenue is tied to successful exits of portfolio companies via IPO or acquisition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Medical Excellence Capital (MEC) is an early-stage life sciences venture capital firm that deploys capital through company creation, seed, Series A, and Series B investments into precision health ventures. The firm combines a proprietary national medical network of 1,100+ physician-scientists across 30+ academic medical centers with experienced VC investors, company creators, and operators to source deals, conduct scientific due diligence, and actively support portfolio companies through board participation.

Product overview

Medical Excellence Capital (MEC) is an early-stage life sciences venture capital firm that does not offer traditional products or services for external customers. The firm provides venture capital investment, company creation support, and operational expertise to early-stage life sciences companies. MEC's investment focus areas include AI for drug discovery, cell and gene therapy, precision medicine, regenerative medicine, synthetic biology, and gene therapy. The firm's portfolio includes companies such as Aspen Neuroscience, Avilar Therapeutics, ClicBio, GC Therapeutics, Immunitas Therapeutics, Ladder Bio, Nobias Therapeutics, Pleno, ProJenX, SonoThera, Trotana Therapeutics, Truvian, and TwoStep Therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• MERIT (Medical Excellence Research Innovation Trust): A philanthropic fund with the mission to advance translational biomedical research for the benefit of humanity, focusing on longevity and chronic disease research themes.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered minor and core.

• Medical Excellence Japan (MEJ)minorStrategic or Co-development Partner · 6 May 2026Medical Excellence Japan signed an MoU with Yamuna Expressway Industrial Development Authority to collaborate on research, investment promotion, and technology transfer in medical devices within a 350-acre Medical Device Park in Noida, India.
• Project ALScoreStrategic or Co-development Partner · 1 January 2021MEC partnered with Project ALS (a nonprofit) to create ProJenX, a clinical-stage biopharma company developing the ALS therapy prosetin derived from Columbia University's Project ALS Therapeutics Core. MEC Managing Partner Eric Heil serves as board chair.
• Medical Excellence Foundation / MERITcoreOthers · 1 January 2019Medical Excellence Foundation is a 501(c)(3) nonprofit founded by MEC to address the 'valley of death' in biomedical research through MERIT (Medical Excellence Research Innovation Trust), providing grants to early-stage scientists. First grant of $50,000 awarded to Project ALS at Columbia University. MEC team provides active oversight and guidance to MERIT grantees.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Atlas Venture: Atlas Venture is a leading early-stage life sciences venture capital firm that builds companies from scratch (analogous to MEC's company-creation model) and invests seed/Series A across therapeutics and platforms. Highly comparable in stage focus, scientific depth, and operator-led investing approach.
• ARCH Venture Partners: ARCH is a premier early-stage life sciences and technology VC firm investing in company formation across biotech, genomics, and platform technologies. Compares directly to MEC given shared focus on deep-science company creation and early-stage therapeutics.
• 5AM Ventures: 5AM Ventures is an early-stage life sciences VC focused on company creation and seed/Series A across platform technologies, gene therapy, and precision medicine. Closely comparable to MEC in stage, therapeutic focus, and company-building approach.
• Versant Ventures: Versant is a healthcare-focused venture firm with a dedicated company-creation engine (Inception Sciences) that mirrors MEC's strategy of building companies alongside academic founders. Highly comparable in life sciences focus and operational company-building model.
• Apple Tree Partners: Apple Tree Partners is a healthcare-only venture firm that builds biotech companies internally and partners with academic founders — closely matching MEC's company-creation thesis across gene therapy, neuroscience, and platform therapeutics.
• Longwood Fund: Longwood Fund is a healthcare-focused VC that co-founded Immunitas Therapeutics with MEC and serves as a key syndication partner. Highly comparable in stage, therapeutics focus, and operator-driven company-building model.

Broad incumbents

• Flagship Pioneering: Flagship Pioneering is a much larger, established life sciences innovation platform that creates and funds biotech companies across multiple therapeutic areas. Comparable in company-creation approach and platform technologies, but at significantly greater scale and capital base than MEC.
• New Enterprise Associates (NEA): NEA is a large, established venture firm with a dedicated healthcare practice investing across stages in biotech and healthtech. Comparable life sciences deal flow but operates at significantly greater scale than MEC.
• OrbiMed: OrbiMed is one of the largest healthcare-dedicated investment firms, investing across stages from seed to public companies in biotech, medtech, and diagnostics. Comparable life sciences mandate but with substantially broader stage coverage and AUM than MEC.
• RA Capital Management: RA Capital is a crossover-focused healthcare investment manager with strong early-stage biotech activity. Comparable in life sciences mandate and syndication presence in MEC's portfolio companies, though much larger and broader across stages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medical Excellence Capital